Zura Bio(DE:94E)
€1.06-2.64 (-67.88%)
DE:94E
Zura Bio financials statements
€1.06
At close:-2.64 (-67.88%)
Zura Bio (94E) Ratios
3 Followers
Zura Bio Ratios
DE:94E's free cash flow for Q3 2026 was $-19.53M. For the 2026 fiscal year, DE:94E's free cash flow was decreased by $-36.00K and operating cash flow was $-19.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Quick Ratio | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Cash Ratio | 8.82 | 9.04 | 4.92 | 0.11 | 2.68 |
| Solvency Ratio | -5.53 | -2.68 | -2.83 | -0.94 | 0.81 |
| Operating Cash Flow Ratio | -5.22 | -1.44 | -0.74 | -0.08 | -4.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -0.15 | 0.00 |
| Net Current Asset Value | $ 99.90M | $ 159.23M | $ 79.55M | $ -25.54M | $ -9.20M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 1.47 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | -0.24 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.32 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.12 | 1.22 | 1.70 | -0.16 | 1.08 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -3.50 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.45 | 0.00 |
| Net Debt to EBITDA | 1.59 | 3.37 | 1.59 | -0.23 | -0.09 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 99.66% | 94.16% | 100.00% |
| EBT Per EBIT | 91.23% | 94.95% | 96.69% | 100.63% | -770.77% |
| Return on Assets (ROA) | -60.25% | -29.19% | -59.86% | -489.13% | 5.99% |
| Return on Equity (ROE) | -67.61% | -35.69% | -101.74% | 80.29% | 6.46% |
| Return on Capital Employed (ROCE) | -74.11% | -34.49% | -77.77% | 284.24% | -0.78% |
| Return on Invested Capital (ROIC) | -74.11% | -34.49% | -77.77% | 1509.00% | -0.78% |
| Return on Tangible Assets | -60.25% | -29.19% | -59.86% | -489.13% | 5.99% |
| Earnings Yield | -13.91% | -27.92% | -41.97% | -20.61% | 6.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.69 | -0.37 | -0.46 | -0.07 | -0.06 |
| Free Cash Flow Per Share | -0.69 | -0.37 | -0.70 | -0.77 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | -573.58 | -374.35 | -1.88 | -0.10 | -274537.42 |
| Capital Expenditure Coverage Ratio | -573.58 | -374.35 | -1.88 | -0.10 | -274537.42 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -0.15 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.16% | -15.00% | -16.03% | -10.57% | -0.88% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.94 | -4.17 | -2.38 | -4.85 | 14.84 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.86 | 1.28 | 2.42 | -3.90 | 0.96 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.60 | -6.67 | -6.24 | -9.46 | -113.73 |
| Price-to-Operating Cash Flow Ratio | -7.61 | -6.68 | -9.55 | -103.90 | -113.73 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | 0.06 | 0.00 | 0.10 | 0.00 |
| Enterprise Value Multiple | -5.60 | -0.21 | -0.70 | -4.83 | 14.75 |
| Enterprise Value | 383.99M | 11.18M | 44.02M | 131.08M | 124.16M |
| EV to EBITDA | -5.60 | -0.21 | -0.70 | -4.83 | 14.75 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -5.91 | -0.40 | -1.91 | -9.93 | -113.06 |
| EV to Operating Cash Flow | -5.92 | -0.40 | -2.92 | -109.05 | -113.06 |
| Tangible Book Value Per Share | 1.08 | 2.13 | 2.41 | -1.28 | 7.55 |
| Shareholders’ Equity Per Share | 1.08 | 1.96 | 1.79 | -1.86 | 7.55 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.73 | -0.70 | -1.83 | -1.49 | 0.49 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.94 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.97 | 1.01 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.94 | 0.54 | 0.25 | 0.04 | -0.13 |
Currency in USD
